Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Nucleic Acid Therapeutics Market By 2029?

The nucleic acid therapeutics market has experienced substantial expansion in recent years. It is projected to increase from $6.01 billion in 2024 to $6.94 billion in 2025, achieving a compound annual growth rate (CAGR) of 15.6%. This historical development can be attributed to a rise in the prevalence of genetic and chronic diseases, intensified research and development within genomics, greater adoption of RNA-based therapeutics, growing support from academic and governmental bodies, and the increasing success of mRNA vaccine platforms.

The nucleic acid therapeutics market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $12.24 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 15.2%. This projected growth during the forecast period is largely driven by factors such as the increasing demand for precision medicine, the broadened applications of mRNA vaccines beyond COVID-19, the emergence of next-generation delivery platforms, an expanding pipeline of nucleic acid-based medications, and more frequent regulatory approvals. Key trends anticipated within the same period encompass the extension of mRNA platforms into areas like oncology and rare diseases, the incorporation of AI and machine learning in the discovery of RNA drugs, the creation of targeted delivery systems for specific tissue actions, the advancement of modular and multi-target platform therapies, and the evolution of next-generation aptamer technologies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27368&type=smp

Which Industry Drivers Are Expected To Accelerate The Nucleic Acid Therapeutics Market From 2025 To 2029?

The growing prevalence of genetic and chronic diseases is anticipated to drive the expansion of the nucleic acid therapeutics market in the future. These diseases encompass the link between inherited genetic elements and the onset, advancement, or risk of enduring health conditions like diabetes, cardiovascular diseases, cancer, and autoimmune disorders. The surge in genetics-linked and chronic illnesses is primarily attributable to enhanced diagnostic technologies that facilitate more precise and earlier identification of these conditions. Nucleic acid therapeutics prove beneficial for genetic and chronic diseases as they can target and alter the fundamental genetic origins of these conditions through the regulation, repair, or silencing of specific genes, providing accurate and customized treatment solutions. For example, as of October 2024, data from the Cystic Fibrosis Trust, a UK charity assisting individuals with cystic fibrosis, showed 11,148 cystic fibrosis patients registered in 2022, increasing to 11,318 in 2023, which signifies a 1.5% year-over-year rise in patient registrations. Consequently, the rising incidence of genetic and chronic diseases is fueling the expansion of the nucleic acid therapeutics market.

What Are The Emerging Segments Gaining Attention In The Nucleic Acid Therapeutics Market?

The nucleic acid therapeutics market covered in this report is segmented

1) By Therapy Type: Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Gene Therapies, Aptamers, Other Therapy Types

2) By Therapeutic Area: Neuromuscular Disorder, Metabolic Disorders, Cardiovascular Disorders, Ophthalmological Disorders, Oncological Disorders, Other Therapeutic Areas

3) By Route Of Administration: Intravenous, Subcutaneous, Other Route Of Administrations

4) By Delivery Method: Viral Vector-Based Delivery Systems, Non-Viral Delivery Systems

5) By End-Use: Pharmaceutical Companies, Government And Academic Research Institutes, Biotech Companies

Subsegment:

1) By Antisense Oligonucleotides (ASOs): Phosphorothioate ASOs, 2’-O-Methyl ASOs, Locked Nucleic Acid (LNA) ASOs, Gapmer ASOs, Morpholino ASOs

2) By Small Interfering RNA (siRNA): Lipid Nanoparticle (LNP) Formulated siRNA, GalNAc-Conjugated siRNA, Chemically Modified siRNA, Naked siRNA

3) By Gene Therapies: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, CRISPR-Based Gene Therapy, Zinc Finger Nucleases (ZFNs), TALENs

4) By Aptamers: Ribonucleic Acid (RNA) Aptamers, Deoxyribonucleic Acid (DNA) Aptamers, Spiegelmers, Pegylated Aptamers

5) By Others Therapy Types: MicroRNA (miRNA) Therapeutics, Long Non-Coding RNA (lncRNA) Therapeutics, Ribonucleic Acid (RNA) Editing Therapies, Ribozymes

What Are The Latest Industry Trends Transforming The Nucleic Acid Therapeutics Market?

Companies within the nucleic acid therapeutics market are concentrating on developing innovative products like antisense oligonucleotide therapy, aiming to target and silence specific disease-causing genes and provide precise treatment options for genetic disorders and rare diseases. Antisense oligonucleotide therapy is a precise treatment utilizing short, synthetic strands of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to either block or alter the expression of particular genes implicated in illnesses. For example, in December 2024, Ionis Pharmaceuticals Inc., a US-based biotechnology firm, obtained U.S. Food and Drug Administration (FDA) approval for TRYNGOLZ (olezarsen). This approval was for its use as an adjunctive therapy alongside diet, intended to reduce triglyceride levels in adults diagnosed with familial chylomicronemia syndrome (FCS), a rare genetic condition marked by severe hypertriglyceridemia (sHTG) and a high likelihood of acute pancreatitis (AP). This particular treatment marks the first FDA-approved solution to achieve significant and lasting triglyceride reduction in this patient group, also demonstrating a notable decrease in AP incidence when combined with a low-fat diet. The therapy is also designed for easy self-administration through a once-monthly auto-injector.

Who Are The Top Performing Companies In The Nucleic Acid Therapeutics Market In Recent Years?

Major companies operating in the nucleic acid therapeutics market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Moderna Inc., BioNTech SE, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Imugene Limited, CureVac SE, Sangamo Therapeutics Inc., Beam Therapeutics Inc., Arbutus Biopharma Corporation, Silence Therapeutics plc, Copernicus Therapeutics Inc., and Exothera S.A.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-therapeutics-global-market-report

What Regional Growth Trends Are Shaping The Nucleic Acid Therapeutics Market Outlook?

North America was the largest region in the nucleic acid therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucleic acid therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Nucleic Acid Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27368&type=smp

Browse Through More Reports Similar to the Global Nucleic Acid Therapeutics Market 2025, By The Business Research Company

Sandwich Panels Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/sandwich-panels-global-market-report

Structural Insulated Panels Market 2025

https://www.thebusinessresearchcompany.com/report/structural-insulated-panels-market

Metal Structural Insulation Panels Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metal-structural-insulation-panels-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.